Want to stay in touch with the latest updates from Pharmaceutical Business review? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: Pharmaceutical Business review
Is this your feed? Claim it!
Under the deal, Teva will hold exclusive rights to commercialise both intravenous and subcutaneous formulations of the biosimilar once it obtains regulatory approval.
The arrangement covers markets, including Australia, Canada, Brazil, Europe, Israel, New Zealand, Turkey, and the US.
Polpharma Biologics will retain full responsibility for developing and manufact...
The company signed the agreement to test the investigational therapy with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Human Genome Research Institute (NHGRI).
Non-profit organisation Ara Parseghian Medical Research Fund will provide financial backing for the multi-year research effort.
Under the agreem...
AstraZeneca will obtain a licence to develop, manufacture and commercialise the phosphodiesterase 3/4 (PDE3/4) inhibitor, TQC3721, outside China.
The agreement also covers certain future development programmes on an exclusive worldwide basis for AstraZeneca.
Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca. The group is also eligi...
Facilitated by Ramot, which manages technology transfer for Tel Aviv University, the agreement will combine computational and experimental tools for academic teams and scientific entrepreneurs seeking to advance early-stage drug candidates.
The partnership will provide a framework connecting Evogene’s AI-based computational chemistry engine, ChemPass AI, with the BCDD’...
The FDA’s Office of Orphan Products Development and Office of Pediatric Therapeutics granted this status to the therapy.
CMT2S is a rare, inherited neurological condition that progressively causes muscle weakness and motor function loss.
VCA-894A is being investigated specifically for a patient who was diagnosed early in life with this rare subtype of Charcot-Ma...